![]() This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage equipment for sample preparation and handling consumables and instruments that help customers in managing samples throughout their research discovery and development workflows. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. SummaryĪzenta beats Olympus on 8 of the 9 factors compared between the two stocks. ![]() Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. 1.7% of Azenta shares are owned by insiders. To read this article on click here.99.5% of Azenta shares are owned by institutional investors. Click to get this free reportĮndo International plc (ENDP) : Free Stock Analysis Reportīaudax Bio, Inc. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.īaudax Bio, Inc.'s revenues are expected to be $0.77 million, up 285% from the year-ago quarter. This company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +82.7%. (BXRX), has yet to report results for the quarter ended June 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Baudax Bio, Inc. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Endo has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Įndo shares have lost about 82.2% since the beginning of the year versus the S&P 500's decline of -13.1%. The company has topped consensus revenue estimates four times over the last four quarters. This compares to year-ago revenues of $713.83 million. Over the last four quarters, the company has surpassed consensus EPS estimates four times.Įndo, which belongs to the Zacks Medical - Drugs industry, posted revenues of $569.11 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 9.01%. A quarter ago, it was expected that this health care company would post earnings of $0.44 per share when it actually produced earnings of $0.66, delivering a surprise of 50%. This quarterly report represents an earnings surprise of 118.75%. These figures are adjusted for non-recurring items. This compares to earnings of $0.65 per share a year ago. Endo International (ENDP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |